INVO Fertility, Inc., a healthcare services company, focuses on the fertility marketplace that provides assisted reproductive technology care to patients. It operates through Fertility Clinic Services and INVOcell Device segments. The company offers INVOcell Device, a medical device that allows fertilization and early embryo development to take place in vivo within the woman's body. It also operates fertility clinics, including INVO Centers. The company was formerly known as NAYA Biosciences, Inc. and changed its name to INVO Fertility, Inc. in April 2025. INVO Fertility, Inc. was founded in 2007 and is based in Sarasota, Florida.…
INVO Fertility Reports Third Quarter 2026 Results Highlighting 28% Clinic Revenue Growth and Continued Positive Clinic-Level Adjusted EBITDA
INVO Fertility Partners with PatientFi to Help Make Fertility Treatment More Affordable
INVO Fertility (NASDAQ: IVF) is listed on Nasdaq, where its shares trade in USD. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 40 employees.
The shares were at 1.760 USD on 20 November 2026, down 98.0% over 52 weeks. Its 52-week range is 1.719 USD to 98.08 USD: the price is 98.2% below the high and 2.4% above the low.
Its market capitalisation is 2.10M USD.
INVO Fertility reports return on equity of -322.8%, an operating margin of -72.2% and revenue up 26.5% year over year.
It holds more cash than debt, a net cash position of 555.38K USD. Its Piotroski F-score is 4 out of 9, an average reading of its financial health.